Publications by authors named "Heidi Ott"

Claim this Profile
D
Distributions for time, interspecies and intraspecies extrapolation for deriving occupational exposure limits.
Marco Dilger, Klaus Schneider, Claudia Drossard, Heidi Ott, Eva Kaiser

J Appl Toxicol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derivation of occupational exposure limits: Differences in methods and protection levels.
Klaus Schneider, Marco Dilger, Claudia Drossard, Heidi Ott, Eva Kaiser

J Appl Toxicol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma.
Allison E Drew, Oscar Moradei, Suzanne L Jacques, Nathalie Rioux, Ann P Boriack-Sjodin, Margaret Porter Scott, Heidi M Ott, Scott A Ribich

Sci Rep· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
Heidi M Ott, Alan P Graves, Melissa B Pappalardi, Michael Huddleston, Wendy S Halsey

Mol Cancer Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long residence time inhibition of EZH2 in activated polycomb repressive complex 2.
Glenn S Van Aller, Melissa Baker Pappalardi, Heidi M Ott, Elsie Diaz, Martin Brandt

ACS Chem Biol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.
Wendy Béguelin, Relja Popovic, Matt Teater, Yanwen Jiang, Karen L Bunting, Heidi M Ott, David W Scott

Cancer Cell· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
Michael T McCabe, Heidi M Ott, Gopinath Ganji, Susan Korenchuk, Christine Thompson

Nature· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
Sharad K Verma, Xinrong Tian, Louis V LaFrance, Céline Duquenne, Dominic P Suarez, Heidi M Ott

ACS Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
Michael T McCabe, Alan P Graves, Gopinath Ganji, Elsie Diaz, Wendy S Halsey, Heidi M Ott

Proc Natl Acad Sci U S A· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
Carl L Manthey, Dana L Johnson, Carl R Illig, Robert W Tuman, Zhao Zhou, Heidi Ott

Mol Cancer Ther· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reassessment of occupational exposure limits.
Hans Stouten, Heidi Ott, Carolien Bouwman, Peter Wardenbach

Am J Ind Med· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors.
Micheal D Gaul, Guozhang Xu, Jennifer Kirkpatrick, Heidi Ott, Christian A Baumann

Bioorg Med Chem Lett· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3.
Raymond J Patch, Christian A Baumann, Jian Liu, Alan C Gibbs, Heidi Ott

Bioorg Med Chem Lett· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors.
Nand Baindur, Naresh Chadha, Benjamin M Brandt, Davoud Asgari, Raymond J Patch, Heidi Ott

J Med Chem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of di-n-butylamine on the respiratory system of Wistar (WU) rats after subchronic inhalation.
Jochen Buschmann, Clemens Dasenbrock, Rainer Fuhst, Gerhard Pohlmann, Wilfried Bartsch, Otto Creutzenberg, Heidi Ott

Inhal Toxicol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis